Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
16 6월 2023 - 8:38PM
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage
biotechnology company developing therapies for patients with kidney
disease, announced today that Company CEO, Shalabh Gupta, MD, has
been invited to present at the Healthcare Virtual Conference Part
II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday,
June 20th to Thursday, June 22nd at 9:00 A.M. ET
This conference will be live on M-Vest. Click Here to Reserve
your seat
About the Maxim Group Virtual Healthcare
ConferenceThe exponential growth in knowledge and
expertise in science and medicine continues to drive opportunities
in the healthcare space. These include multiple therapeutic
categories and emerging technologies, which our presenting
companies at this year's Maxim Healthcare Conference are focused
on, and for many, that includes key data-driven events in 2023.
Maxim Senior Analysts will host a wide range of biotechnology and
medical device companies in a series of presentations and
interactive discussions with CEOs and key management. Maxim will
also be hosting several topical industry panels that promise to be
timely and engaging.
About M-VestM-Vest is a division of Maxim Group
LLC that serves to allow investors to access investment
opportunities online and to provide a digital community built for
issuers, investors, and thought leaders to share information. The
platform provides insights on current market trends through
presentations from innovative emerging growth companies and
commentary from industry thought leaders via live events and
Q&A.
About Unicycive TherapeuticsUnicycive
Therapeutics is a biotechnology company developing novel treatments
for kidney diseases. Unicycive’s lead drug, lanthanum
dioxycarbonate (LDC), is a novel investigational phosphate binding
agent being developed for the treatment of hyperphosphatemia in
chronic kidney disease patients on dialysis. UNI-494 is a
patent-protected new chemical entity in late preclinical
development for the treatment of acute kidney injury. For more
information, please visit www.unicycive.com.
Forward-looking
statementsCertain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
using words such as "anticipate," "believe," "forecast,"
"estimated" and "intend" or other similar terms or expressions that
concern Unicycive's expectations, strategy, plans or intentions.
These forward-looking statements are based on Unicycive's current
expectations and actual results could differ materially. There are
several factors that could cause actual events to differ materially
from those indicated by such forward-looking statements. These
factors include, but are not limited to, clinical trials involve a
lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of
future trial results; our clinical trials may be suspended or
discontinued due to unexpected side effects or other safety risks
that could preclude approval of our product candidates; risks
related to business interruptions, including the outbreak of
COVID-19 coronavirus, which could seriously harm our financial
condition and increase our costs and expenses; dependence on key
personnel; substantial competition; uncertainties of patent
protection and litigation; dependence upon third parties; and risks
related to failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties related to market conditions and other factors
described more fully in the section entitled ‘Risk Factors’ in
Unicycive’s Annual Report on Form 10-K for the year ended December
31, 2021, and other periodic reports filed with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Unicycive
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Investor Contact:
ir@unicycive.com(650) 900-5470
Unicycive Therapeutics (NASDAQ:UNCY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Unicycive Therapeutics (NASDAQ:UNCY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024